HC Wainwright Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $113.00 price objective on the stock. HC Wainwright’s target price would indicate a potential downside of 9.39% from the stock’s current price.

Several other analysts have also recently issued reports on the stock. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research note on Friday, August 2nd. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. TD Cowen reduced their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and increased their target price for the stock from $91.00 to $125.00 in a research report on Monday. Finally, Jefferies Financial Group boosted their price objective on shares of BioNTech from $90.00 to $96.00 and gave the stock a “hold” rating in a research note on Friday, September 13th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.00.

BioNTech Stock Up 1.0 %

BNTX stock opened at $124.71 on Monday. BioNTech has a one year low of $76.53 and a one year high of $131.49. The stock has a market capitalization of $29.65 billion, a P/E ratio of 249.42 and a beta of 0.23. The company has a 50 day moving average price of $88.13 and a two-hundred day moving average price of $89.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter last year, the company posted ($0.86) earnings per share. The business’s quarterly revenue was down 23.3% compared to the same quarter last year. As a group, sell-side analysts expect that BioNTech will post -2.8 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares in the last quarter. Frazier Financial Advisors LLC bought a new position in shares of BioNTech in the 4th quarter worth about $30,000. Covestor Ltd lifted its position in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. Finally, Crewe Advisors LLC bought a new stake in shares of BioNTech during the 1st quarter valued at about $75,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.